Sign inJoin waitlistJoin the waitlist

Jonathan Goldman

Member/Health Sciences Clinical · Santa Monica-UCLA Medical Center

Credentials: · · · · ·

History

Santa Monica-UCLA Medical Center
Present

Hematology and Medical Oncology
2004–2007
Internal Medicine
2001–2004
Stanford University School of Medicine
1997–2001

Research

Pembrolizumab for the treatment of non-small-cell lung cancer
New England Journal of Medicine · 2015 · 5,237 citations
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label,…
The Lancet · 2019 · 1,945 citations
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2020 · 1,546 citations

Edward Garon
35 papers
Lee Rosen
16 papers
Ross Camidge
15 papers
Xiuning Le
14 papers
Aaron Lisberg
12 papers
Amy Cummings
11 papers
HY
Helena Yu
11 papers
Jonathan Riess
11 papers
MH
Matthew Hellmann
11 papers · 1 as a fellow
RH
Roy Herbst
11 papers
ZP
Zofia Piotrowska
11 papers · 2 as a fellow
Marina Garassino
10 papers

Clinical trials

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2026–2028
Ivonescimab for the Treatment of Thymic Cancer
Principal investigator · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2025–2028
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Principal investigator · Active not recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2025–2029
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2022–2032